PMV Pharmaceuticals, Inc.

PMVP Healthcare Biotechnology

In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.

1.21 0.08 −6.20%
Market cap
$97.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
— 26.75 22.57 56.91 24.66 22.80 14.78 12.22 10.09
Net Debt/EBITDA
— 3.40 3.88 10.48 5.19 3.13 2.42 1.89 1.27
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.87 0.87 0.95 0.81 0.87 0.81 0.87 0.95
Capex/Depreciation
— (0.69) (0.24) (0.31) (1.57) 25.51 0.23 0.10 0.00
ROE
— 30.08% 43.48% (23.86%) (17.33%) (26.44%) (29.24%) (29.23%) (55.37%)
ROA
— 0.00% (49.21%) (14.70%) (16.60%) (24.36%) (26.40%) (26.48%) (50.51%)
ROIC
— 0.00% 0.00% 0.00% (344.55%) (1,159.68%) (229.63%) (805.99%) 0.00%
Return on Tangible Assets
— (28.78%) (25.79%) (9.60%) (19.80%) (29.67%) (33.80%) (36.31%) (74.72%)
Research and Development Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
— (5.19) (7.31) (2.29) (1.06) (1.57) (1.18) (1.00) (1.40)
Cash per Share
— 20.55 33.44 25.16 6.60 5.30 4.25 3.29 2.15
Shareholders Equity per Share
— 0.00 (23.22) 25.00 6.84 5.40 4.70 3.41 1.99
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 0.00 (23.22) 25.00 6.84 5.40 4.70 3.41 1.99
Free Cash Flow
— (15.63) (22.17) (32.89) (47.92) (71.74) (56.62) (51.69) (73.57)
Working Capital
— 59.91 97.57 358.35 289.07 236.17 193.38 161.29 103.81
Capital Expenditures
— (0.45) (0.11) (0.15) (1.35) (7.98) (0.96) (0.40) 0.00
Net Current Asset Value
— 62.24 (71.41) 358.35 278.28 222.73 180.95 160.45 103.38
Other line items
Quick Ratio
— 26.60 22.44 56.38 24.39 22.33 14.53 11.79 9.89
Depreciation/Fixed assets
— 0.65 0.61 0.83 0.28 (0.03) (0.39) (10.33) (11.13)
Cash ROIC
— (25.25%) (71.50%) (4.56%) (7.90%) (14.70%) (13.18%) (14.96%) (33.80%)
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 0.00 0.00 — — —
Revenue per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
— (5.04) (7.27) (2.28) (1.03) (1.40) (1.16) (0.99) (1.40)
Capex per Share
— (0.15) (0.04) (0.01) (0.03) (0.18) (0.02) (0.01) 0.00
Average Payables
— 1.94 1.94 2.22 2.40 3.09 3.12 4.91 4.87
Average Assets
— 0.00 51.52 234.28 348.55 300.94 261.23 221.72 153.93
Average Common Equity
— (58.31) (58.31) 144.32 333.84 277.29 235.86 200.88 140.40
Capex to Sales
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates